tubulin beta 8 class VIII pseudogene 6Genealiases: []
Q-omics provides the consensus-scored TUBB8P6 profile across patient tissues and cancer cell-line models. TUBB8P6 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TUBB8P6 is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, TUBB8P6 RNA expression shows 5,759 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LUAD, ESCA, and UCEC as cancer lineages where TUBB8P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB8P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB8P6 survival associations across molecular data types. TUBB8P6 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB8P6 RNA expression–survival associations across cancer types. High TUBB8P6 expression shows unfavorable associations in LUAD, KIRP, UCS, DLBC and KICH, but favorable associations in CESC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TUBB8P6 RNA expression.
This table summarizes TUBB8P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for TUBB8P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB8P6 shows higher tumor expression in ESCA and COAD. The ESCA box plot shows higher TUBB8P6 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .007).
This table shows molecular features associated with TUBB8P6 in patient tissues and cancer cell lines. In patient samples, TUBB8P6 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
